Form 8-K - Current report:
SEC Accession No. 0001213900-25-062194
Filing Date
2025-07-09
Accepted
2025-07-09 08:05:27
Documents
15
Period of Report
2025-07-08
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248394-8k_jasper.htm   iXBRL 8-K 33568
2 PRESS RELEASE, DATED JULY 9, 2025 ea024839401ex99-1_jasper.htm EX-99.1 15506
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6939
  Complete submission text file 0001213900-25-062194.txt   277027

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE jspr-20250708.xsd EX-101.SCH 3897
5 XBRL DEFINITION FILE jspr-20250708_def.xml EX-101.DEF 26812
6 XBRL LABEL FILE jspr-20250708_lab.xml EX-101.LAB 37092
7 XBRL PRESENTATION FILE jspr-20250708_pre.xml EX-101.PRE 25436
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0248394-8k_jasper_htm.xml XML 5985
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 251112305
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)